FDA Approves New Combination Vaccine for Children
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves New Combination Vaccine for Children

NEW YORK -- June 25, 2008 -- The US Food and Drug Administration (FDA) has approved Kinrix(TM) [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine], a combination vaccine to offer protection against diphtheria, tetanus, pertussis, and polio diseases in 1 shot.

"Children aged 4 to 6 years can receive 5 or more vaccinations in a single visit, which can be stressful for parents and vaccinators," said William P. Hitchcock, MD, University of California, San Diego School of Medicine, San Diego, California.

"By reducing the number of shots given in 1 visit, combination vaccines like Kinrix may make it easier for kids to meet school vaccination requirements and CDC [Centers for Disease Control and Prevention] recommendations."

Clinical studies of Kinrix have demonstrated that this new combination vaccine offers similar protection to the separately administered diphtheria and tetanus toxoids, acellular pertussis (DTaP), and inactivated poliovirus (IPV) vaccines, with a comparable safety profile.

Kinrix is approved for children aged 4 to 6 years whose previous diphtheria, tetanus toxoids, and DTaP vaccinations have been with Pediarix(R) [Diphtheria, Tetanus Toxoids, Acellular Pertussis, Hepatitis B (Recombinant), and Inactivated Poliovirus Vaccine] and/or Infanrix(R) [Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed].

In clinical studies, common adverse events were injection-site reactions (pain, redness, swelling, or increase in arm circumference), drowsiness, fever, and loss of appetite. Previous hypersensitivity to any component of Kinrix, including neomycin and polymyxin B, is a contraindication.

SOURCE: GlaxoSmithKline

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities